Recent Updates
Recently added Catalysts
RDY

Dr. Reddy's Laboratories Ltd . 8-2-337, Road No. 3, Banjara Hills Hyderabad - 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.

Key Takeaway: National Stock Exchange of India Ltd. (Scrip Code: DRREDDY) BSE Limited (Scrip Code: 500124) New York Stock Exchange Inc. (Stock Code: RDY) NSE IFSC Ltd. (Stock Code: DRREDDY) This is to inform that the Company has received five separate orders from GST Authority towards tax

Full Press Release Details

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
This is to inform that the Company has received five separate orders from GST Authority towards tax demand including interest and levying penalty for the period FY 2018-19 to FY 2022-23. The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are as hereunder:
S.No. Name of the authority : Joint Commissioner, Office of Principal Commissioner of Central Tax, Visakhapatnam
1 Nature and details of the action(s) taken, or order(s) passed : The Company has received such orders seeking demand including interest and levying penalty under APGST Act 2017.
2 Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority : Orders dated December 31, 2025, were received by the Company on December 31, 2025.
3 Details of the violation(s)/ contravention(s) committed or alleged to be committed : The authority has passed the orders on the ground that the Company has availed excess input tax credit.
4 Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible : The above orders levy penalty as detailed below: Financial Year Penalty (INR) FY 2018-19 1,89,30,110 FY 2019-20 80,41,186 FY 2020-21 3,52,95,063 FY 2021-22 1,45,04,023 FY 2022-23 70,86,675 Based on our evaluation, there is no material impact on the financials, operations, or other activities of the Company.
The Company will evaluate filing necessary appeal with the appellate authority in this regard.
This is for your information and records.
For Dr. Reddy's Laboratories Limited
Company Secretary, Compliance Officer & Head-CSR
Last updated: Jan 1, 2026